BRG1-IN-1 is a potent BRG1 inhibitor that sensitizes glioblastoma (GBM) cells to the antiproliferative and cell death-inducing effects of Temozolomide in vitro, demonstrating superior efficacy compared to PFI-3; it also enhances Temozolomide-mediated suppression of subcutaneous GBM tumor growth.